Khalid Benbatoul

666 total citations
25 papers, 564 citations indexed

About

Khalid Benbatoul is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Khalid Benbatoul has authored 25 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Genetics and 7 papers in Oncology. Recurrent topics in Khalid Benbatoul's work include Chronic Lymphocytic Leukemia Research (9 papers), Acute Myeloid Leukemia Research (6 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Khalid Benbatoul is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Acute Myeloid Leukemia Research (6 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Khalid Benbatoul collaborates with scholars based in United States, Sweden and Germany. Khalid Benbatoul's co-authors include Sonja Krane, Edmund J. Moran, Ross Dixon, Chengzhi Zhang, Lawrence D. Mayer, Roy T. Uyeda, Emma S. Tomlinson Guns, Suzanne J. Romano, Michael Newman and Sepehr Sarshar and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.

In The Last Decade

Khalid Benbatoul

25 papers receiving 542 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Khalid Benbatoul United States	10	284	232	116	72	52	25	564
Ken‐ichi Akamatsu United States	14	357 1.3×	292 1.3×	74 0.6×	36 0.5×	22 0.4×	31	793
Y.-H. Ling United States	13	333 1.2×	226 1.0×	46 0.4×	57 0.8×	19 0.4×	24	582
Benjamin F. Chu United States	8	209 0.7×	241 1.0×	48 0.4×	13 0.2×	41 0.8×	8	517
Sita Kugel Desmoulin United States	12	450 1.6×	91 0.4×	75 0.6×	22 0.3×	135 2.6×	12	692
Anna M. Azarova United States	8	743 2.6×	502 2.2×	128 1.1×	26 0.4×	13 0.3×	9	1.2k
Ronald Drengler United States	13	296 1.0×	487 2.1×	17 0.1×	24 0.3×	41 0.8×	27	701
Yelena Zabelina United States	7	485 1.7×	223 1.0×	32 0.3×	20 0.3×	11 0.2×	12	712
Gary Wilkinson United Kingdom	10	327 1.2×	179 0.8×	125 1.1×	23 0.3×	5 0.1×	23	546
Michael Rosenbach United States	9	374 1.3×	132 0.6×	24 0.2×	63 0.9×	8 0.2×	9	671

Countries citing papers authored by Khalid Benbatoul

Since Specialization

Citations

This map shows the geographic impact of Khalid Benbatoul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khalid Benbatoul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khalid Benbatoul more than expected).

Fields of papers citing papers by Khalid Benbatoul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khalid Benbatoul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khalid Benbatoul. The network helps show where Khalid Benbatoul may publish in the future.

Co-authorship network of co-authors of Khalid Benbatoul

This figure shows the co-authorship network connecting the top 25 collaborators of Khalid Benbatoul. A scholar is included among the top collaborators of Khalid Benbatoul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khalid Benbatoul. Khalid Benbatoul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rastgoo, Nasrin, Matthew Thayer, Khalid Benbatoul, et al.. (2020). Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas. Cancer Research. 80(16_Supplement). 4225–4225. 2 indexed citations

Zhang, Hongying, Nasrin Rastgoo, Khalid Benbatoul, et al.. (2020). Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas. Cancer Research. 80(16_Supplement). CT239–CT239. 1 indexed citations

Bejar, Rafael, Hongying Zhang, Nasrin Rastgoo, et al.. (2020). A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS. Blood. 136(Supplement 1). 45–46. 4 indexed citations

Benbatoul, Khalid, et al.. (2019). PF203 CG‐806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN‐FLT3/PAN‐BTK INHIBITOR. HemaSphere. 3(S1). 54–54. 1 indexed citations

Local, Andrea, Hongying Zhang, Khalid Benbatoul, et al.. (2018). APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells. Molecular Cancer Therapeutics. 17(6). 1177–1186. 68 indexed citations

Zhang, Hongying, Andrea Local, Khalid Benbatoul, et al.. (2018). CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells. Blood. 132(Supplement 1). 3503–3503. 2 indexed citations

Zhang, Hongying, Andrea Local, Khalid Benbatoul, et al.. (2017). CG '806, a Highly Potent First-in-Class Pan-FLT3/BTK Inhibitor, Targets Multiple Clusters of Kinases Operative in Diverse Subtypes of Acute Myeloid Leukemia. Blood. 130. 5063–5063. 1 indexed citations

Local, Andrea, Hongying Zhang, Khalid Benbatoul, et al.. (2017). APTO-253 Interaction with G-Quadruplex DNA Is Linked to Inhibition of c-Myc Expression, Induction of DNA Damage, and Generation of Synthetic Lethality in Cells with BRCA1/2 Impairment. Blood. 130. 5094–5094. 2 indexed citations

Zhang, Hongying, Andrea Local, Khalid Benbatoul, et al.. (2017). CG '806, a First-in-Class Non-Covalent Pan-FLT3/BTK Inhibitor, Exerts Superior Potency Against B-Cell Malignant Cells. Blood. 130. 5200–5200. 2 indexed citations

10.

Kurtz, Stephen E., Beth Wilmot, Shannon K. McWeeney, et al.. (2017). Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes. Clinical Cancer Research. 23(24_Supplement). 44–44. 1 indexed citations

11.

Zhang, Hongying, Andrea Local, Khalid Benbatoul, et al.. (2016). Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia. Blood. 128(22). 1716–1716. 3 indexed citations

12.

Miner, Jeffrey N., Khalid Benbatoul, Christopher J. Larson, et al.. (2007). Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein–protein interaction profile. Proceedings of the National Academy of Sciences. 104(49). 19244–19249. 55 indexed citations

13.

Purandare, Ashok V., Honghe Wan, Naomi Laing, et al.. (2004). Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome. Bioorganic & Medicinal Chemistry Letters. 14(18). 4701–4704. 15 indexed citations

14.

Zhang, Chengzhi, Sepehr Sarshar, Edmund J. Moran, et al.. (2001). ChemInform Abstract: 2,4,5‐Trisubstituted Imidazoles: Novel Nontoxic Modulators of P‐Glycoprotein Mediated Multidrug Resistance. Part 2.. ChemInform. 32(14). 3 indexed citations

15.

Sarshar, Sepehr, et al.. (2000). 2,4,5-三置換イミダゾール P-糖蛋白質媒介多剤耐性の新規無毒モジュレータ 2. Bioorganic & Medicinal Chemistry Letters. 10(23). 2603–2605. 18 indexed citations

16.

Christen, R D, Dennis Gately, Khalid Benbatoul, et al.. (2000). Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel. Cancer Chemotherapy and Pharmacology. 45(5). 381–388. 9 indexed citations

17.

Zhang, Chengzhi, Sepehr Sarshar, Edmund J. Moran, et al.. (2000). 2,4,5-Trisubstituted imidazoles. Bioorganic & Medicinal Chemistry Letters. 10(23). 2603–2605. 53 indexed citations

18.

Sarshar, Sepehr, Chengzhi Zhang, Edmund J. Moran, et al.. (2000). 2,4,5-Trisubstituted imidazoles. Bioorganic & Medicinal Chemistry Letters. 10(23). 2599–2601. 37 indexed citations

19.

Newman, Michael, Khalid Benbatoul, Suzanne J. Romano, et al.. (2000). Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.. PubMed. 60(11). 2964–72. 160 indexed citations

20.

Tran, Yen, Khalid Benbatoul, Karen Gorse, et al.. (1998). Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. Oncogene. 17(26). 3499–3505. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact